241 related articles for article (PubMed ID: 30901021)
1. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
3. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
4. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
[TBL] [Abstract][Full Text] [Related]
5. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
7. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
8. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
9. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
[TBL] [Abstract][Full Text] [Related]
11. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
13. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
O'Donnell MR; Padayatchi N; Daftary A; Orrell C; Dooley KE; Rivet Amico K; Friedland G
Lancet HIV; 2019 Mar; 6(3):e201-e204. PubMed ID: 30846058
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
[TBL] [Abstract][Full Text] [Related]
16. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
[No Abstract] [Full Text] [Related]
17. A review of tuberculosis: Focus on bedaquiline.
Chan B; Khadem TM; Brown J
Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
[TBL] [Abstract][Full Text] [Related]
18. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
Bouton TC; de Vos M; Ragan EJ; White LF; Van Zyl L; Theron D; Horsburgh CR; Warren RM; Jacobson KR
PLoS One; 2019; 14(10):e0223308. PubMed ID: 31622366
[TBL] [Abstract][Full Text] [Related]
19. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
20. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
